BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 23, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2001

View Archived Issues

New series of chemokine receptor-binding compounds and uses reported by AnorMED

Read More

Modulators of dopamine neurotransmission presented in recent patents

Read More

ADIR patents novel treatments for endothelial dysfunction

Read More

Three related series of PDE4 inhibitors in development at Icos

Read More

Endothelin receptor antagonists identified by Actelion team

Read More

Liver-specific MRI contrast agent launched in Sweden

Read More

Modified second-generation taxoids: design and SAR discussed at ACS

Read More

Pfizer presents new sulfonamide-based compounds with high selectivity for MMP-3

Read More

Simplified salicylihalimide analogues which retain antitumor activity

Read More

BTG obtains rights to ANF peptide technology from Genentech

Read More

Antidiabetic effects of GW-0072, a new SPARM, examined in animal model of type 2 diabetes

Read More

Zeria licenses rights to Visicol from InKine

Read More

Glucose excursion decreased, formation of new beta-cells enhanced by DPP IV inhibitor

Read More

Jomed and Oxigene form collaboration on restenosis inhibitors

Read More

Positive results obtained in phase II Chronogesic trial for long-term pain relief

Read More

Orally active NO-independent sGC stimulators from Bayer with vasodilating and hypotensive activity

Read More

HGS initiates new clinical trial with repifermin for treatment of mucositis

Read More

Janssen seeks FDA approval of new long-acting Risperdal formulation

Read More

Ortec's OrCel approved for healing donor site wounds in burn victims

Read More

Phase I trials commence for another peripheral kappa opioid receptor agonist from Adolor

Read More

Epicyte and Dow collaborate with Centocor on production of therapeutic MAbs in plants

Read More

New HCV target discovered at Myriad Genetics, drug development program initiated

Read More

WHI-P131: a dual-acting antileukemic, anti-GVHD compound targeting JAK3

Read More

Cellegy seeks MCA approval of Rectogesic for treatment of anal fissures

Read More

Data from first study in female Fabry's disease patients discussed at recent workshop

Read More

Maxygen and InterMune to develop next-generation interferon gamma products

Read More

Pivotal trials of daptomycin advance in anticipation of 2003 launch

Read More

Gene transfer of COX-1 proves to restore PGI2 synthesis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing